Kennedy Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Kennedy Capital Management’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.2M	Buy	1,240,692 +26,723	+2%	+$177K	0.15%	228
2025 Q4	$9.53M	Buy	1,213,969 +2,386	+0.2%	+$18.8K	0.2%	173
2025 Q3	$9.86M	Buy	1,211,583 +395,436	+48%	+$2.63M	0.22%	159
2025 Q2	$3.81M	Buy	816,147 +81,060	+11%	+$371K	0.09%	336
2025 Q1	$4.04M	Buy	735,087 +68,992	+10%	+$279K	0.1%	322
2024 Q4	$2.26M	Buy	666,095 +61,238	+10%	+$197K	0.05%	494
2024 Q3	$1.72M	Buy	+604,857	New	+$1.55M	0.04%	536

Other funds holding XERS

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT)

Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $244M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return